From BRCA1to polygenic risk scores: mutation-associated risks in breast cancer-related genes
AffiliationManchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester
MetadataShow full item record
AbstractBackground: There has been huge progress over the last 30 years in identifying the familial component of breast cancer. Summary: Currently around 20% is explained by the high-risk genes BRCA1 and BRCA2, a further 2% by other high-penetrance genes, and around 5% by the moderate risk genes ATM and CHEK2. In contrast, the more than 300 low-penetrance single-nucleotide polymorphisms (SNP) now account for around 28% and they are predicted to account for most of the remaining 45% yet to be found. Even for high-risk genes which confer a 40-90% risk of breast cancer, these SNP can substantially affect the level of breast cancer risk. Indeed, the strength of family history and hormonal and reproductive factors is very important in assessing risk even for a BRCA carrier. The risks of contralateral breast cancer are also affected by SNP as well as by the presence of high or moderate risk genes. Genetic testing using gene panels is now commonplace. Key-messages: There is a need for a more parsimonious approach to panels only testing those genes with a definite 2-fold increased risk and only testing those genes with challenging management implications, such as CDH1 and TP53, when there is strong clinical indication to do so. Testing of SNP alongside genes is likely to provide a more accurate risk assessment.
CitationWoodward ER, van Veen EM, Evans DG. From BRCA1 to Polygenic Risk Scores: Mutation-Associated Risks in Breast Cancer-Related Genes. Breast Care. 2021;16(3):202–13.
- Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
- Authors: Gallagher S, Hughes E, Wagner S, Tshiaba P, Rosenthal E, Roa BB, Kurian AW, Domchek SM, Garber J, Lancaster J, Weitzel JN, Gutin A, Lanchbury JS, Robson M
- Issue date: 2020 Jul 1
- Common breast cancer risk variants in the post-COGS era: a comprehensive review.
- Authors: Maxwell KN, Nathanson KL
- Issue date: 2013 Dec 20
- The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
- Authors: Bunnell AE, Garby CA, Pearson EJ, Walker SA, Panos LE, Blum JL
- Issue date: 2017 Feb
- Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
- Authors: Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC
- Issue date: 2006 Mar 22
- Hereditary breast cancer; Genetic penetrance and current status with BRCA.
- Authors: Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R, Pillai S, Lam AK, Gopalan V
- Issue date: 2019 May